Старение, воспаление и гликирование

8. Литература

    1. Ashraf J. M., Ahmad S., Choi I., Ahmad N., Farhan M., Tatyana G., et al. . (2015). Recent advances in detection of AGEs: immunochemical, bioanalytical and biochemical approaches. IUBMB Life 67, 897–913. 10.1002/iub.1450 - DOI - PubMed
    1. Aso Y., Inukai T., Tayama K., Takemura Y. (2000). Serum concentrations of advanced glycation endproducts are associated with the development of atherosclerosis as well as diabetic microangiopathy in patients with type 2 diabetes. Acta Diabetol. 37, 87–92. 10.1007/s005920070025 - DOI - PubMed
    1. Baig M. H., Jan A. T., Rabbani G., Ahmad K., Ashraf J. M., Kim T., et al. . (2017). Methylglyoxal and advanced glycation end products: insight of the regulatory machinery affecting the myogenic program and of its modulation by natural compounds. Sci. Rep. 7:5916. 10.1038/s41598-017-06067-5 - DOI - PMC - PubMed
    1. Baulmann J., Nurnberger J., Slany J., Schmieder R., Schmidt-Trucksass A., Baumgart D., et al. (2010). [Arterial stiffness and pulse wave analysis]. Dtsch. Med. Wochenschr. 135(Suppl. 1), S4–S14. 10.1055/s-0030-1249183 - DOI - PubMed
    1. Brouwers O., Niessen P. M., Ferreira I., Miyata T., Scheffer P. G., Teerlink T., et al. . (2011). Overexpression of glyoxalase-I reduces hyperglycemia-induced levels of advanced glycation end products and oxidative stress in diabetic rats. J. Biol. Chem. 286, 1374–1380. 10.1074/jbc.M110.144097 - DOI - PMC - PubMed
    1. Brouwers O., Niessen P. M., Miyata T., Ostergaard J. A., Flyvbjerg A., Peutz-Kootstra C. J., et al. . (2014). Glyoxalase-1 overexpression reduces endothelial dysfunction and attenuates early renal impairment in a rat model of diabetes. Diabetologia 57, 224–235. 10.1007/s00125-013-3088-5 - DOI - PubMed
    1. Bucciarelli L. G., Wendt T., Qu W., Lu Y., Lalla E., Rong L. L., et al. . (2002). RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106, 2827–2835. 10.1161/01.CIR.0000039325.03698.36 - DOI - PubMed
    1. Cai W., Gao Q.-D., Zhu L., Peppa M., He C., Vlassara H. (2002). Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol. Med. 8, 337–346. - PMC - PubMed
    1. Campbell D. J., Somaratne J. B., Jenkins A. J., Prior D. L., Yii M., Kenny J. F., et al. . (2011). Impact of type 2 diabetes and the metabolic syndrome on myocardial structure and microvasculature of men with coronary artery disease. Cardiovasc. Diabetol. 10, 80–80. 10.1186/1475-2840-10-80 - DOI - PMC - PubMed
    1. Campbell D. J., Somaratne J. B., Jenkins A. J., Prior D. L., Yii M., Kenny J. F., et al. . (2012). Diastolic dysfunction of aging is independent of myocardial structure but associated with plasma advanced glycation end-product levels. PLoS ONE 7:e49813. 10.1371/journal.pone.0049813 - DOI - PMC - PubMed
    1. Chang J. S., Wendt T., Qu W., Kong L., Zou Y. S., Schmidt A. M., et al. . (2008). Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ. Res. 102, 905–913. 10.1161/CIRCRESAHA.107.165308 - DOI - PubMed
    1. Chavakis T., Bierhaus A., Nawroth P. P. (2004). RAGE (receptor for advanced glycation end products): a central player in the inflammatory response. Microb. Infect. 6, 1219–1225. 10.1016/j.micinf.2004.08.004 - DOI - PubMed
    1. Choi K. M., Yoo H. J., Kim H. Y., Lee K. W., Seo J. A., Kim S. G., et al. . (2009). Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int. J. Cardiol. 132, 96–101. 10.1016/j.ijcard.2007.10.047 - DOI - PubMed
    1. Daffu G., del Pozo C. H., O'Shea K. M., Ananthakrishnan R., Ramasamy R., Schmidt A. M. (2013). Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int. J. Mol. Sci. 14, 19891–19910. 10.3390/ijms141019891 - DOI - PMC - PubMed
    1. Da Moura Semedo C., Webb M., Waller H., Khunti K., Davies M. (2017). Skin autofluorescence, a non-invasive marker of advanced glycation end products: clinical relevance and limitations. Postgrad. Med. J. 93, 289–294. 10.1136/postgradmedj-2016-134579 - DOI - PubMed
    1. Forbes J. M., Yee L. T., Thallas V., Lassila M., Candido R., Jandeleit-Dahm K. A., et al. . (2004). Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53, 1813–1823. 10.2337/diabetes.53.7.1813 - DOI - PubMed
    1. Gaballa M. A., Jacob C. T., Raya T. E., Liu J., Simon B., Goldman S. (1998). Large artery remodeling during aging: biaxial passive and active stiffness. Hypertension 32, 437–443. 10.1161/01.HYP.32.3.437 - DOI - PubMed
    1. Gao X., Zhang H., Schmidt A. M., Zhang C. (2008). AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am. J. Physiol. Heart Circ. Physiol. 295, H491–H498. 10.1152/ajpheart.00464.2008 - DOI - PMC - PubMed
    1. Giacco F., Du X., D'Agati V. D., Milne R., Sui G., Geoffrion M., et al. . (2014). Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. Diabetes 63, 291–299. 10.2337/db13-0316 - DOI - PMC - PubMed
    1. Goldin A., Beckman J. A., Schmidt A. M., Creager M. A. (2006). Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114, 597–605. 10.1161/CIRCULATIONAHA.106.621854 - DOI - PubMed
    1. Greenwald S. E. (2007). Ageing of the conduit arteries. J. Pathol. 211, 157–172. 10.1002/path.2101 - DOI - PubMed
    1. Gu Q., Wang B., Zhang X. F., Ma Y. P., Liu J. D., Wang X. Z. (2014). Contribution of receptor for advanced glycation end products to vasculature-protecting effects of exercise training in aged rats. Eur. J. Pharmacol. 741, 186–194. 10.1016/j.ejphar.2014.08.017 - DOI - PubMed
    1. Hadi H. A. R., Suwaidi J. A. (2007). Endothelial dysfunction in diabetes mellitus. Vasc. Health Risk Manag. 3, 853–876. - PMC - PubMed
    1. Hallam K. M., Li Q., Ananthakrishnan R., Kalea A., Zou Y. S., Vedantham S., et al. . (2010). Aldose reductase and AGE–RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats. Aging Cell 9, 776–784. 10.1111/j.1474-9726.2010.00606.x - DOI - PMC - PubMed
    1. Hanford L. E., Enghild J. J., Valnickova Z., Petersen S. V., Schaefer L. M., Schaefer T. M., et al. . (2004). Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J. Biol. Chem. 279, 50019–50024. 10.1074/jbc.M409782200 - DOI - PMC - PubMed
    1. He C., Sabol J., Mitsuhashi T., Vlassara H. (1999). Dietary glycotoxins: inhibition of reactive products by aminoguanidine facilitates renal clearance and reduces tissue sequestration. Diabetes 48, 1308–1315. 10.2337/diabetes.48.6.1308 - DOI - PubMed
    1. Henning C., Glomb M. A. (2016). Pathways of the Maillard reaction under physiological conditions. Glycoconj. J. 33, 499–512. 10.1007/s10719-016-9694-y - DOI - PubMed
    1. Herold K., Moser B., Chen Y., Zeng S., Yan S. F., Ramasamy R., et al. . (2007). Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress. J. Leukoc. Biol. 82, 204–212. 10.1189/jlb.1206751 - DOI - PubMed
    1. Hudson B. I., Kalea A. Z., Del Mar Arriero M., Harja E., Boulanger E., D'Agati V., et al. . (2008). Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J. Biol. Chem. 283, 34457–34468. 10.1074/jbc.M801465200 - DOI - PMC - PubMed
    1. Izzo J. L., Jr. (2004). Arterial stiffness and the systolic hypertension syndrome. Curr. Opin. Cardiol. 19, 341–352. 10.1097/01.hco.0000126581.89648.10 - DOI - PubMed
    1. Jo-Watanabe A., Ohse T., Nishimatsu H., Takahashi M., Ikeda Y., Wada T., et al. . (2014). Glyoxalase I reduces glycative and oxidative stress and prevents age-related endothelial dysfunction through modulation of endothelial nitric oxide synthase phosphorylation. Aging Cell 13, 519–528. 10.1111/acel.12204 - DOI - PMC - PubMed
    1. Kaess B. M., Rong J., Larson M. G., Hamburg N. M., Vita J. A., Levy D., et al. . (2012). Aortic stiffness, blood pressure progression, and incident hypertension. JAMA 308, 875–881. 10.1001/2012.jama.10503 - DOI - PMC - PubMed
    1. Kalea A. Z., Reiniger N., Yang H., Arriero M., Schmidt A. M., Hudson B. I. (2009). Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J. 23, 1766–1774. 10.1096/fj.08-117739 - DOI - PMC - PubMed
    1. Kass D. A., Shapiro E. P., Kawaguchi M., Capriotti A. R., Scuteri A., deGroof R. C., et al. . (2001). Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation 104, 1464–1470. 10.1161/hc3801.097806 - DOI - PubMed
    1. Kay A. M., Simpson C. L., Stewart J. A. (2016). The role of AGE/RAGE signaling in diabetes-mediated vascular calcification. J. Diabetes Res. 2016:6809703. 10.1155/2016/6809703 - DOI - PMC - PubMed
    1. Kislinger T., Tanji N., Wendt T., Qu W., Lu Y., Ferran L. J., Jr., et al. . (2001). Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 21, 905–910. 10.1161/01.ATV.21.6.905 - DOI - PubMed
    1. Koch M., Chitayat S., Dattilo B. M., Schiefner A., Diez J., Chazin W. J., et al. . (2010). Structural basis for ligand recognition and activation of RAGE. Structure 18, 1342–1352. 10.1016/j.str.2010.05.017 - DOI - PMC - PubMed
    1. Lakatta E. G., Levy D. (2003). Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a “set up” for vascular disease. Circulation 107, 139–146. 10.1161/01.CIR.0000048892.83521.58 - DOI - PubMed
    1. Lakatta E. G., Sollott S. J. (2002). Perspectives on mammalian cardiovascular aging: humans to molecules. Comp. Biochem. Physiol. Part A Mol. Integr. Physiol. 132, 699–721. 10.1016/S1095-6433(02)00124-1 - DOI - PubMed
    1. Laurent S., Boutouyrie P., Asmar R., Gautier I., Laloux B., Guize L., et al. . (2001). Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37, 1236–1241. 10.1161/01.HYP.37.5.1236 - DOI - PubMed
    1. Li H., Horke S., Förstermann U. (2014). Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis 237, 208–219. 10.1016/j.atherosclerosis.2014.09.001 - DOI - PubMed
    1. Luevano-Contreras C., Chapman-Novakofski K. (2010). Dietary advanced glycation end products and aging. Nutrients 2, 1247–1265. 10.3390/nu2121247 - DOI - PMC - PubMed
    1. Lutgers H. L., Gerrits E. G., Graaff R., Links T. P., Sluiter W. J., Gans R. O., et al. . (2009). Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 52, 789–797. 10.1007/s00125-009-1308-9 - DOI - PubMed
    1. Manigrasso M. B., Pan J., Rai V., Zhang J., Reverdatto S., Quadri N., et al. . (2016). Small molecule inhibition of ligand-stimulated RAGE-DIAPH1 signal transduction. Sci. Rep. 6:22450. 10.1038/srep22450 - DOI - PMC - PubMed
    1. Mattace-Raso F. U., van der Cammen T. J., Hofman A., van Popele N. M., Bos M. L., Schalekamp M. A., et al. . (2006). Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 113, 657–663. 10.1161/CIRCULATIONAHA.105.555235 - DOI - PubMed
    1. McNulty M., Mahmud A., Feely J. (2007). Advanced glycation end-products and arterial stiffness in hypertension. Am. J. Hypertens. 20, 242–247. 10.1016/j.amjhyper.2006.08.009 - DOI - PubMed
    1. Meerwaldt R., Graaff R., Oomen P. H. N., Links T. P., Jager J. J., Alderson N. L., et al. . (2004). Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 47, 1324–1330. 10.1007/s00125-004-1451-2 - DOI - PubMed
    1. Montezano A. C., Touyz R. M. (2014). Reactive oxygen species, vascular noxs, and hypertension: focus on translational and clinical research. Antioxid. Redox Signal. 20, 164–182. 10.1089/ars.2013.5302 - DOI - PMC - PubMed
    1. Mozaffarian D., Benjamin E. J., Go A. S., Arnett D. K., Blaha M. J., Cushman M., et al. (2016). Executive summary: heart disease and stroke statistics−2016 update: a report from the american heart association. Circulation 133, 447–454. 10.1161/CIR.0000000000000366 - DOI - PubMed
    1. Münch G., Keis R., Wessels A., Riederer P., Bahner U., Heidland A., et al. . (1997). Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur. J. Clin. Chem. Clin. Biochem. 35, 669–677. 10.1515/cclm.1997.35.9.669 - DOI - PubMed
    1. Najjar S. S., Scuteri A., Lakatta E. G. (2005). Arterial aging: is it an immutable cardiovascular risk factor? Hypertension 46, 454–462. 10.1161/01.HYP.0000177474.06749.98 - DOI - PubMed
    1. Noordzij M. J., Lefrandt J. D., Loeffen E. A., Saleem B. R., Meerwaldt R., Lutgers H. L., et al. . (2012). Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease. Int. J. Cardiovasc. Imaging 28, 431–438. 10.1007/s10554-011-9805-6 - DOI - PMC - PubMed
    1. Park L., Raman K. G., Lee K. J., Lu Y., Ferran L. J., Jr., Chow W. S., et al. . (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4, 1025–1031. 10.1038/2012 - DOI - PubMed
    1. Pepe S., Lakatta E. G. (2005). Aging hearts and vessels: masters of adaptation and survival. Cardiovasc. Res. 66, 190–193. 10.1016/j.cardiores.2005.03.004 - DOI - PubMed
    1. Peppa M., Raptis S. A. (2008). Advanced glycation end products and cardiovascular disease. Curr. Diabetes Rev. 4, 92–100. 10.2174/157339908784220732 - DOI - PubMed
    1. Pitt J. J. (2009). Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry. Clin. Biochem. Rev. 30, 19–34. - PMC - PubMed
    1. Rabbani N., Thornalley P. J. (2014). The critical role of methylglyoxal and glyoxalase 1 in diabetic nephropathy. Diabetes 63, 50–52. 10.2337/db13-1606 - DOI - PubMed
    1. Rai V., Maldonado A. Y., Burz D. S., Reverdatto S., Schmidt A. M., Shekhtman A. (2012). Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of c-terminal rage (ctRAGE) and its binding to mDia1. J. Biol. Chem. 287, 5133–5144. 10.1074/jbc.M111.277731 - DOI - PMC - PubMed
    1. Reddy G. K. (2004). AGE-related cross-linking of collagen is associated with aortic wall matrix stiffness in the pathogenesis of drug-induced diabetes in rats. Microvasc. Res. 68, 132–142. 10.1016/j.mvr.2004.04.002 - DOI - PubMed
    1. Reiniger N., Lau K., McCalla D., Eby B., Cheng B., Lu Y., et al. . (2010). Deletion of the receptor for advanced glycation end products reduces glomerulosclerosis and preserves renal function in the diabetic OVE26 mouse. Diabetes 59, 2043–2054. 10.2337/db09-1766 - DOI - PMC - PubMed
    1. Rubattu S., Mennuni S., Testa M., Mennuni M., Pierelli G., Pagliaro B., et al. . (2013). Pathogenesis of chronic cardiorenal syndrome: is there a role for oxidative stress? Int. J. Mol. Sci. 14, 23011–23032. 10.3390/ijms141123011 - DOI - PMC - PubMed
    1. Sabbagh M. N., Agro A., Bell J., Aisen P. S., Schweizer E., Galasko D. (2011). PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 25, 206–212. 10.1097/WAD.0b013e318204b550 - DOI - PMC - PubMed
    1. Safar M. E., Levy B. I., Struijker-Boudier H. (2003). Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 107, 2864–2869. 10.1161/01.CIR.0000069826.36125.B4 - DOI - PubMed
    1. Schleicher E. D., Wagner E., Nerlich A. G. (1997). Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J. Clin. Invest. 99, 457–468. 10.1172/JCI119180 - DOI - PMC - PubMed
    1. Schmidt A. M., Yan S. D., Wautier J. L., Stern D. (1999). Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84, 489–497. 10.1161/01.RES.84.5.489 - DOI - PubMed
    1. Sell D. R., Monnier V. M. (2012). Molecular basis of arterial stiffening: role of glycation - a mini-review. Gerontology 58, 227–237. 10.1159/000334668 - DOI - PubMed
    1. Semba R. D., Sun K., Schwartz A. V., Varadhan R., Harris T. B., Satterfield S., et al. . (2015). Serum carboxymethyl-lysine, an advanced glycation end product, is associated with arterial stiffness in older adults. J. Hypertens. 33, 797–803; discussion: 803. 10.1097/HJH.0000000000000460 - DOI - PMC - PubMed
    1. Sethi S., Rivera O., Oliveros R., Chilton R. (2014). Aortic stiffness: pathophysiology, clinical implications, and approach to treatment. Integr. Blood Press. Control 7, 29–34. 10.2147/IBPC.S59535 - DOI - PMC - PubMed
    1. Sims T. J., Rasmussen L. M., Oxlund H., Bailey A. J. (1996). The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 39, 946–951. 10.1007/BF00403914 - DOI - PubMed
    1. Singh V. P., Bali A., Singh N., Jaggi A. S. (2014). Advanced glycation end products and diabetic complications. Korean J. Physiol. Pharmacol. 18, 1–14. 10.4196/kjpp.2014.18.1.1 - DOI - PMC - PubMed
    1. Soulis T., Thallas V., Youssef S., Gilbert R. E., McWilliam B. G., Murray-McIntosh R. P., et al. . (1997). Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40, 619–628. 10.1007/s001250050725 - DOI - PubMed
    1. Spinetti G., Wang M., Monticone R., Zhang J., Zhao D., Lakatta E. G. (2004). Rat aortic MCP-1 and its receptor CCR2 increase with age and alter vascular smooth muscle cell function. Arterioscler. Thromb. Vasc. Biol. 24, 1397–1402. 10.1161/01.ATV.0000134529.65173.08 - DOI - PubMed
    1. Sprague A. H., Khalil R. A. (2009). Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem. Pharmacol. 78, 539–552. 10.1016/j.bcp.2009.04.029 - DOI - PMC - PubMed
    1. Stitt A. W., He C., Friedman S., Scher L., Rossi P., Ong L., et al. . (1997). Elevated AGE-modified ApoB in sera of euglycemic, normolipidemic patients with atherosclerosis: relationship to tissue AGEs. Mol. Med. 3, 617–627. - PMC - PubMed
    1. Strait J. B., Lakatta E. G. (2012). Aging-associated cardiovascular changes and their relationship to heart failure. Heart Fail. Clin. 8, 143–164. 10.1016/j.hfc.2011.08.011 - DOI - PMC - PubMed
    1. Stürmer M., Šebeková K., Fazeli G., Bahner U., Stäb F., Heidland A. (2015). 25-hydroxyvitamin d and advanced glycation endproducts in healthy and hypertensive subjects: are there interactions? J. Ren. Nutr. 25, 209–216. 10.1053/j.jrn.2014.10.027 - DOI - PubMed
    1. Takeuchi M., Makita Z., Yanagisawa K., Kameda Y., Koike T. (1999). Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol. Med. 5, 393–405. - PMC - PubMed
    1. Tan A. L., Forbes J. M., Cooper M. E. (2007). AGE, RAGE, and ROS in diabetic nephropathy. Semin. Nephrol. 27, 130–143. 10.1016/j.semnephrol.2007.01.006 - DOI - PubMed
    1. Tanaka K., Tani Y., Asai J., Nemoto F., Kusano Y., Suzuki H., et al. . (2012). Skin autofluorescence is associated with severity of vascular complications in Japanese patients with type 2 diabetes. Diabet. Med. 29, 492–500. 10.1111/j.1464-5491.2011.03448.x - DOI - PubMed
    1. Touré F., Fritz G., Li Q., Rai V., Daffu G., Zou Y. S., et al. . (2012). Formin mDia1 mediates vascular remodeling via integration of oxidative and signal transduction pathways. Circ. Res. 110, 1279–1293. 10.1161/CIRCRESAHA.111.262519 - DOI - PMC - PubMed
    1. Uribarri J., del Castillo M. D., de la Maza M. P., Filip R., Gugliucci A., Luevano-Contreras C., et al. . (2015). Dietary advanced glycation end products and their role in health and disease. Adv. Nutr. 6, 461–473. 10.3945/an.115.008433 - DOI - PMC - PubMed
    1. Vaitkevicius P. V., Lane M., Spurgeon H., Ingram D. K., Roth G. S., Egan J. J., et al. . (2001). A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc. Natl. Acad. Sci. U.S.A. 98, 1171–1175. 10.1073/pnas.98.3.1171 - DOI - PMC - PubMed
    1. Vikramadithyan R. K., Hu Y., Noh H. L., Liang C. P., Hallam K., Tall A. R., et al. . (2005). Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J. Clin. Invest. 115, 2434–2443. 10.1172/JCI24819 - DOI - PMC - PubMed
    1. Wang M., Zhang J., Jiang L. Q., Spinetti G., Pintus G., Monticone R., et al. . (2007). Proinflammatory profile within the grossly normal aged human aortic wall. Hypertension 50, 219–227. 10.1161/HYPERTENSIONAHA.107.089409 - DOI - PubMed
    1. Wautier J. L., Wautier M. P., Schmidt A. M., Anderson G. M., Hori O., Zoukourian C., et al. . (1994). Advanced Glycation End Products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc. Natl. Acad. Sci. U.S.A. 91, 7742–7746. 10.1073/pnas.91.16.7742 - DOI - PMC - PubMed
    1. Wautier M. P., Chappey O., Corda S., Stern D. M., Schmidt A. M., Wautier J. L. (2001). Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. Endocrinol. Metab. 280, E685–E694. - PubMed
    1. Wu M. S., Liang J. T., Lin Y. D., Wu E. T., Tseng Y. Z., Chang K. C. (2008). Aminoguanidine prevents the impairment of cardiac pumping mechanics in rats with streptozotocin and nicotinamide-induced type 2 diabetes. Br. J. Pharmacol. 154, 758–764. 10.1038/bjp.2008.119 - DOI - PMC - PubMed
    1. Xu B., Chibber R., Ruggiero D., Kohner E., Ritter J., Ferro A. (2003). Impairment of vascular endothelial nitric oxide synthase activity by advanced glycation end products. FASEB J. 17, 1289–1291. 10.1096/fj.02-0490fje - DOI - PubMed
    1. Xu Y., Toure F., Qu W., Lin L., Song F., Shen X., et al. . (2010). Advanced glycation end product (AGE)-receptor for AGE (RAGE) signaling and up-regulation of Egr-1 in hypoxic macrophages. J. Biol. Chem. 285, 23233–23240. 10.1074/jbc.M110.117457 - DOI - PMC - PubMed
    1. Xue J., Ray R., Singer D., Böhme D., Burz D. S., Rai V., et al. . (2014). The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs. Biochemistry 53, 3327–3335. 10.1021/bi500046t - DOI - PMC - PubMed
    1. Yamagishi S., Yonekura H., Yamamoto Y., Katsuno K., Sato F., Mita I., et al. . (1997). Advanced glycation end products-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem. 272, 8723–8730. 10.1074/jbc.272.13.8723 - DOI - PubMed
    1. Yan S. D., Schmidt A. M., Anderson G. M., Zhang J., Brett J., Zou Y. S., et al. . (1994). Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 269, 9889–9897. - PubMed
    1. Yan S. F., Ramasamy R., Naka Y., Schmidt A. M. (2003). Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ. Res. 93, 1159–1169. 10.1161/01.RES.0000103862.26506.3D - DOI - PubMed
    1. Yonekura H., Yamamoto Y., Sakurai S., Petrova R. G., Abedin M. J., Li H., et al. . (2003). Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370, 1097–1109. 10.1042/bj20021371 - DOI - PMC - PubMed
    1. Zieman S. J., Melenovsky V., Clattenburg L., Corretti M. C., Capriotti A., Gerstenblith G., et al. . (2007). Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J. Hypertens. 25, 577–583. 10.1097/HJH.0b013e328013e7dd - DOI - PubMed